Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.

Author: AhnHeejung, ChoYoung-Jae, ChoiHyoung Sook, ChoiSun Mi, HahnSeokyung, HanJiyeon, HeoEun Young, HwangYong Ran, JeongIna, JoYong Suk, JohJoon-Sung, KiJongeun, KimDeog Kyeom, KimHyeonjeong, KimHyun Su, KimJunghyun, KimSe Joong, KwakNakwon, LeeChang-Hoon, LeeJae Ho, LeeJi Yeon, LeeJinwoo, LeeJung-Kyu, LeeMyungsun, LeeSang Hoon, LeeSang-Min, LeeYeon Joo, LimJi Na, ParkJong Sun, ParkJu-Hee, ParkSung Soo, ParkYoung Sik, SongTaeksun, YimJae-Joon, YoonHo Il

Paper Details 
Original Abstract of the Article :
BACKGROUND: Linezolid improves the treatment outcomes of multidrug-resistant tuberculosis substantially. We investigated whether use of linezolid instead of ethambutol increases the proportion of sputum culture conversion at 8 weeks of treatment in patients with pulmonary tuberculosis. METHODS: We ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/S1473-3099(18)30480-8

データ提供:米国国立医学図書館(NLM)

Linezolid: A New Weapon in the Fight Against Tuberculosis

The world of infectious diseases is a vast and treacherous desert, filled with challenges and threats. Tuberculosis (TB) remains a significant public health concern, a formidable foe that requires innovative strategies to combat its spread. This study, like a scientific expedition venturing into uncharted territory, investigates the potential of linezolid, a potent antibiotic, in the treatment of pulmonary TB. The researchers, armed with their scientific tools, conducted a randomized clinical trial comparing linezolid to ethambutol, a standard TB medication. Their findings, like a map revealing a new route, suggest that while linezolid did not demonstrate a significant advantage over ethambutol in terms of sputum culture conversion, it offers a safe and effective alternative with a favorable resistance profile, paving the way for potential applications in shortening treatment durations. The study also highlights the importance of continued research to explore the optimal use of linezolid in TB treatment.

A New Approach to TB Treatment

The study explores the potential of linezolid as a valuable addition to the arsenal of TB treatment options, offering a new path toward achieving faster and more effective outcomes. The findings contribute to the ongoing effort to improve TB treatment strategies, potentially leading to shorter treatment durations and better patient outcomes.

Navigating the Desert of TB

TB, like a persistent desert wind, continues to pose a threat to global health. This research, like a compass guiding through the desert, provides valuable insights into the potential of linezolid and the importance of continued research to develop new and effective treatment strategies to combat this formidable foe.

Dr.Camel's Conclusion

This study, like a camel caravan traversing a vast desert, represents a journey toward better TB treatment. While linezolid may not offer a groundbreaking breakthrough, its safety, effectiveness, and potential for shortening treatment durations make it a valuable addition to the toolkit for combating this challenging disease. The research serves as a reminder that the quest for better TB treatments continues, with each new study bringing us closer to a healthier future.

Date :
  1. Date Completed 2020-05-08
  2. Date Revised 2020-05-08
Further Info :

Pubmed ID

30477961

DOI: Digital Object Identifier

10.1016/S1473-3099(18)30480-8

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.